FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286294118> ?p ?o ?g. }

• W4286294118 endingPage "TPS5107" @default.
• W4286294118 startingPage "TPS5107" @default.
• W4286294118 abstract "TPS5107 Background: Despite a growing number of treatment options for first line mCRPC, approximately 40% of patients (pts) have radiographic progression within the first year. Androgen receptor (AR) signaling inhibition increases genomic instability with double-strand DNA breaks & co-inhibition of AR & PARP induces synthetic lethality in multiple preclinical models. Homologous recombination repair (HRR) gene aberrations do not appear to be necessary for this synergy as demonstrated in a ph 3 clinical trial of abiraterone & olaparib where this combination improved radiographic progression-free survival (rPFS) in HRR-wild-type pts compared with abiraterone alone. A ph 1b trial has since shown that enzalutamide plus rucaparib has acceptable safety profile & no significant drug-drug interactions (S-DDI). Methods: CASPAR/A031902 (NCT04455750) is a ph 3 study in which 984 pts will be randomized 1:1 to enzalutamide plus rucaparib or placebo. HRR gene aberration is not required for enrollment. All pts will undergo next-generation targeted-exome sequencing from archival tumor tissue (new biopsy only required if no archival tissue available). Treatment will be continued until disease progression & crossover is not allowed. Key eligibility criteria are age ≥ 18 years, ECOG PS 0-2, biopsy-proven prostate adenocarcinoma, progressive (PSA or radiographic) disease per Prostate Cancer Working Group 3 guidelines, measurable or nonmeasurable disease per RECIST 1.1, no prior treatment for mCRPC (prior docetaxel, abiraterone, darolutamide, or apalutamide in non-mCRPC setting is allowed), no significant uncontrolled comorbidity, & no medications with S-DDI with enzalutamide/rucaparib. Hierarchical co-primary endpoints are rPFS & overall survival (OS). The OS analysis will be undertaken as a primary endpoint if the rPFS endpoint is met. For a one-sided logrank test with a type 1 error rate equal to 0.025, the study has 90% power to detect a hazard ratio (HR) of 0.71 in rPFS (median rPFS of 15 & 21 months in control & combination arms, respectively) & 80% power to detect an HR of 0.80 in OS (median OS of 32 & 40 months, respectively). Key secondary endpoints are rPFS & OS in pts with vs without pathogenic BRCA1, BRCA2, or PALB2 alterations; & differences in adverse events & quality of life (QOL) outcomes between the treatment arms. QOL assessments include Functional Assessment of Cancer Therapy–Prostate (FACT-P), Brief Pain Inventory Short Form (BPI-SF) & EQ-5D-5L. A key correlative endpoint is the sensitivity of ctDNA-based testing for alterations in HRR genes. Enrollment to CASPAR began in July 2021 & the study is available for participation to all US-NCTN sites with a projected enrollment of 3 years. Support: U10CA180821, U10CA180882, U24CA196171; U10CA180888. Clinical trial information: NCT04455750." @default.
• W4286294118 created "2022-07-21" @default.
• W4286294118 creator A5004689576 @default.
• W4286294118 creator A5012804612 @default.
• W4286294118 creator A5017288060 @default.
• W4286294118 creator A5020260247 @default.
• W4286294118 creator A5021900842 @default.
• W4286294118 creator A5024278705 @default.
• W4286294118 creator A5031035765 @default.
• W4286294118 creator A5053588971 @default.
• W4286294118 creator A5061064382 @default.
• W4286294118 creator A5072272174 @default.
• W4286294118 creator A5074874280 @default.
• W4286294118 creator A5076269626 @default.
• W4286294118 creator A5078699439 @default.
• W4286294118 creator A5080500055 @default.
• W4286294118 creator A5090009905 @default.
• W4286294118 date "2022-06-01" @default.
• W4286294118 modified "2023-09-30" @default.
• W4286294118 title "Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)." @default.
• W4286294118 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps5107" @default.
• W4286294118 hasPublicationYear "2022" @default.
• W4286294118 type Work @default.
• W4286294118 citedByCount "1" @default.
• W4286294118 countsByYear W42862941182022 @default.
• W4286294118 crossrefType "journal-article" @default.
• W4286294118 hasAuthorship W4286294118A5004689576 @default.
• W4286294118 hasAuthorship W4286294118A5012804612 @default.
• W4286294118 hasAuthorship W4286294118A5017288060 @default.
• W4286294118 hasAuthorship W4286294118A5020260247 @default.
• W4286294118 hasAuthorship W4286294118A5021900842 @default.
• W4286294118 hasAuthorship W4286294118A5024278705 @default.
• W4286294118 hasAuthorship W4286294118A5031035765 @default.
• W4286294118 hasAuthorship W4286294118A5053588971 @default.
• W4286294118 hasAuthorship W4286294118A5061064382 @default.
• W4286294118 hasAuthorship W4286294118A5072272174 @default.
• W4286294118 hasAuthorship W4286294118A5074874280 @default.
• W4286294118 hasAuthorship W4286294118A5076269626 @default.
• W4286294118 hasAuthorship W4286294118A5078699439 @default.
• W4286294118 hasAuthorship W4286294118A5080500055 @default.
• W4286294118 hasAuthorship W4286294118A5090009905 @default.
• W4286294118 hasConcept C104317684 @default.
• W4286294118 hasConcept C121608353 @default.
• W4286294118 hasConcept C126322002 @default.
• W4286294118 hasConcept C142724271 @default.
• W4286294118 hasConcept C143998085 @default.
• W4286294118 hasConcept C182979987 @default.
• W4286294118 hasConcept C203092338 @default.
• W4286294118 hasConcept C204787440 @default.
• W4286294118 hasConcept C27081682 @default.
• W4286294118 hasConcept C2775832370 @default.
• W4286294118 hasConcept C2776551883 @default.
• W4286294118 hasConcept C2777899217 @default.
• W4286294118 hasConcept C2779962180 @default.
• W4286294118 hasConcept C2780192828 @default.
• W4286294118 hasConcept C535046627 @default.
• W4286294118 hasConcept C54355233 @default.
• W4286294118 hasConcept C61367390 @default.
• W4286294118 hasConcept C71924100 @default.
• W4286294118 hasConcept C82381507 @default.
• W4286294118 hasConcept C86803240 @default.
• W4286294118 hasConceptScore W4286294118C104317684 @default.
• W4286294118 hasConceptScore W4286294118C121608353 @default.
• W4286294118 hasConceptScore W4286294118C126322002 @default.
• W4286294118 hasConceptScore W4286294118C142724271 @default.
• W4286294118 hasConceptScore W4286294118C143998085 @default.
• W4286294118 hasConceptScore W4286294118C182979987 @default.
• W4286294118 hasConceptScore W4286294118C203092338 @default.
• W4286294118 hasConceptScore W4286294118C204787440 @default.
• W4286294118 hasConceptScore W4286294118C27081682 @default.
• W4286294118 hasConceptScore W4286294118C2775832370 @default.
• W4286294118 hasConceptScore W4286294118C2776551883 @default.
• W4286294118 hasConceptScore W4286294118C2777899217 @default.
• W4286294118 hasConceptScore W4286294118C2779962180 @default.
• W4286294118 hasConceptScore W4286294118C2780192828 @default.
• W4286294118 hasConceptScore W4286294118C535046627 @default.
• W4286294118 hasConceptScore W4286294118C54355233 @default.
• W4286294118 hasConceptScore W4286294118C61367390 @default.
• W4286294118 hasConceptScore W4286294118C71924100 @default.
• W4286294118 hasConceptScore W4286294118C82381507 @default.
• W4286294118 hasConceptScore W4286294118C86803240 @default.
• W4286294118 hasFunder F4320315087 @default.
• W4286294118 hasFunder F4320332161 @default.
• W4286294118 hasIssue "16_suppl" @default.
• W4286294118 hasLocation W42862941181 @default.
• W4286294118 hasOpenAccess W4286294118 @default.
• W4286294118 hasPrimaryLocation W42862941181 @default.
• W4286294118 hasRelatedWork W2309274182 @default.
• W4286294118 hasRelatedWork W2770702948 @default.
• W4286294118 hasRelatedWork W2776594178 @default.
• W4286294118 hasRelatedWork W3023947295 @default.
• W4286294118 hasRelatedWork W3132581442 @default.
• W4286294118 hasRelatedWork W3166684626 @default.
• W4286294118 hasRelatedWork W3197069188 @default.
• W4286294118 hasRelatedWork W4226040508 @default.
• W4286294118 hasRelatedWork W4281724514 @default.
• W4286294118 hasRelatedWork W4297477309 @default.
• W4286294118 hasVolume "40" @default.

• next